David A. Siegel Infla Rx N.V. Transaction History

Two Sigma Advisers, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.25 - $2.75 $31,125 - $68,475	24,900 New	24,900 $40,000
Q4 2020 Feb 16, 2021	SELL	$3.82 - $5.32 $167,338 - $233,047	-43,806 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.7 - $5.47 $66,230 - $97,913	-17,900 Reduced 29.01%	43,806 $187,000
Q2 2020 Aug 14, 2020	SELL	$4.59 - $8.96 $101,439 - $198,016	-22,100 Reduced 26.37%	61,706 $283,000
Q1 2020 May 15, 2020	SELL	$2.65 - $6.08 $70,755 - $162,336	-26,700 Reduced 24.16%	83,806 $320,000
Q4 2019 Feb 14, 2020	BUY	$2.2 - $4.54 $18,700 - $38,590	8,500 Added 8.33%	110,506 $438,000
Q3 2019 Nov 14, 2019	BUY	$2.47 - $3.51 $251,954 - $358,041	102,006 New	102,006 $252,000

12.9M

19.3K

Ticker IFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,203,800
Market Cap $77.4M
Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.